Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease-Reference-Cited by-同舟云学术

Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease

Published:2022-06 Issue:6 Volume:175 Page:774-782
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Holt Anders¹^ORCID,Blanche Paul²^ORCID,Jensen Aksel Karl Georg²^ORCID,Nouhravesh Nina¹,Rajan Deepthi¹^ORCID,Jensen Mads Hashiba¹^ORCID,El-Sheikh Mohammed¹^ORCID,Schjerning Anne-Marie³,Schou Morten¹,Gislason Gunnar⁴^ORCID,Torp-Pedersen Christian⁵^ORCID,McGettigan Patricia⁶^ORCID,Lamberts Morten¹^ORCID

Affiliation:

1. Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark (A.H., N.N., D.R., M.H.J., M.E., M.S., M.L.)

2. Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark (P.B., A.K.G.J.)

3. Department of Cardiology, Zealand University Hospital, Roskilde, and The Danish Heart Foundation, Copenhagen, Denmark (A.S.)

4. Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, and The Danish Heart Foundation, Copenhagen, Denmark (G.G.)

5. Department of Clinical Research, North Zealand Hospital, Hillerød, and Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark (C.T.)

6. William Harvey Research Institute, Queen Mary University of London, London, United Kingdom (P.M.).

Funder

Dagmar Marshalls Fond

Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond

Marie og M.B. Richters Fond

Ib Mogens Kristiansens Almene Fond

Helsefonden

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Reference28 articles.